Karolinska University Hospital
Stockholm, 17176, Sweden
Location status: Recruiting
Location contact
Giedre Grigelioniene, MD, PhD
CONTACT
Hillevi Lindelöf, MD
CONTACT
NCT Number: NCT05876416
This 5-year project aims to (1) search for genetic causes for yet unsolved congenital skeletal disorders (GSDs); (2) study consequences of the newly identified pathogenic variants in cells and in transgenic mice, (3) summarize data on natural course and complications for different GSD groups. For patients with unsolved GSD, the investigators search for molecular causes of GSDs using whole genome sequencing (WGS) and total ribonucleic acid (RNA) sequencing. Candidate gene variants are selected using genome or transcriptome sequencing data, clinical findings and screening of omics databases. Causality of the new variants is studied in cells and in transgenic mice models. Molecular and clinical findings are summarized for different GSD groups.
Interested in participating?
Request InfoAll sexes
Observational
Stockholm, 17176, Sweden
Location status: Recruiting
Giedre Grigelioniene, MD, PhD
CONTACT
Hillevi Lindelöf, MD
CONTACT
Genetic skeletal disorders (GSDs) are a large group of rare diseases caused by abnormalities in genes regulating skeletal development. This 5-year project aims to (1) search for genetic causes for yet unsolved congenital skeletal disorders; (2) study consequences of the newly identified pathogenic variants in cells and in transgenic mice, (3) summarize data on natural course and complications for different GSD groups. The project is a collaboration between the Dept of Clinical Genetics, Karolinska University Hospital, Lab of Clinical Genetics and Lab of Bone and Cartilage Physiology, Karolinska Institutet and Sahlgrenska Academy. In a well-characterized group of 300 GSD participants whose DNA samples were analyzed using whole genome sequencing (WGS), there are 120 study participants with unsolved diagnoses. For those participants, we search for molecular causes of GSDs using WGS and total RNA sequencing. Candidate gene variants are selected using genome or transcriptome sequencing data, clinical findings and screening of omics databases. Causality of the new variants is studied in cells and in transgenic mice models. Molecular and clinical findings are summarized for different GSD groups. Our results improve diagnostics for GSDs, advance knowledge on pathogenesis and help establishing new individual follow-up and treatment strategies for patients with GSDs. This project increases understanding of skeletal pathophysiology and will contribute to the development of novel treatment methods for skeletal diseases.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Clinically suspected skeletal dysplasia based on previous investigations
Abnormal height
Radiographic abnormalities of the skeleton in addition to other syndromic features
Healthy relatives of the affected study participants
Exclusion criteria
No radiographic data available from clinical investigations
Suspected environmental or multifactorial causes
Time frame: 2023-2028
2-3 new disease causes and disease entities identified and reported per year for GSDs.
Time frame: 2023-2028
1-2 GSDs reported as small patient groups with the same condition and clinical characteristics/course.
Time frame: 2023-2028
The observations include internal malformations, metabolic, biochemical and growth parameters, and secondary complications.
Time frame: 2023-2028
During the study we identify several novel disease causing variants in known GSD genes and report them to databases.
Contact information is provided by the study sponsor or research team.
Giedre Grigelioniene, MD, PhD
CONTACT
Hillevi Lindelöf, MD
CONTACT
Karolinska Institutet
Other
Acronym: SKDLAND
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05247645
Carbohydrate Metabolism, Inborn Errors, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Bologna, Emilia-Romagna, Italy
View Trial DetailsNCT03548779
Autism Spectrum Disorder, Brain Diseases
Asheville, North Carolina, United States
View Trial DetailsNCT05991609
Carbohydrate Metabolism, Inborn Errors, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Bath, United Kingdom
View Trial DetailsNCT05031507
Bone Diseases, Bone Diseases, Developmental
Bethesda, Maryland, United States
View Trial Details